Clinical Trial Update: A Study of APG-3288 in Relapsed/Refractory Blood Cancers [Phase 1]

View source ↗

Summary

Phase 1 study of APG-3288 in relapsed/refractory hematologic cancers; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Richter Syndrome
• Waldenström Macroglobulinemia

Drugs mentioned

• APG-3288

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL | Phase 1 | Status: NOT_YET_RECRUITING